FDA Cancer Drug Approvals in 2017

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

In the phase 2 EPOCI1802 trial, atezolizumab monotherapy elicited a cCR rate of 42.1%, an ORR of 65.8%, and a 12-month OS rate of 65.8% in advanced ESCC.

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.